低对比剂剂量肝脏CT联合深度学习去噪低单能图像评估肝细胞癌:随机对照非劣效试验
结果显示低剂量组HCC清晰度非劣效于标准剂量组(2.92 vs 2.56,差异0.36,95%CI -0.13至∞,p=0.013),HCC检出率两组相当。
要点
- 低对比剂剂量联合50-keV深度学习去噪可减少40%对比剂用量而不损害动脉期HCC显示清晰度。
- 低剂量组动脉期HCC清晰度非劣效于标准剂量组MBIR图像(非劣效界值0.2)。
- 两组HCC检出率相当,支持该技术在HCC高危人群中的应用。
关键影像表现/征象
- 动脉期低剂量组50-keV深度学习去噪图像的HCC清晰度评分为2.92,标准剂量组MBIR图像为2.56。
- 低剂量组对比剂用量为64.5±11.3 mL,标准剂量组为107.0±17.1 mL。
诊断标准与关键数值
- HCC清晰度非劣效性检验:低剂量组50-keV DLD图像与标准剂量组MBIR图像的差异为0.36(95%CI -0.13至∞),非劣效界值0.2,p=0.013,达到非劣效。
- HCC检出率在低剂量组50-keV DLD图像与标准剂量组MBIR图像之间具有可比性。
临床应用与阅片要点
- 对HCC高危患者行肝脏CT增强检查时,可采用低对比剂剂量(减少40%)联合50-keV单能图像和深度学习去噪技术,以降低对比剂负荷。
- 阅片时注意低剂量组图像为50-keV DLD重建,与标准剂量MBIR图像风格不同,但HCC动脉期强化显示清晰度非劣效。
局限性
- 非劣效性检验的置信区间上限为无穷,仅验证非劣效而非优效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Low monoenergetic images obtained using noise-reduction techniques may reduce CT contrast media requirements. We aimed to investigate the effectiveness of low-contrast-dose CT using dual-energy CT and deep learning-based denoising (DLD) techniques in patients at high risk of hepatocellular carcinoma (HCC).
METHODS: We performed a prospective, randomized controlled noninferiority trial at a tertiary hospital between June 2019 and August 2020 (NCT04027556). Patients at high risk of HCC were randomly assigned (1:1) to the standard-contrast-dose group or low-contrast-dose group, which targeted a 40% reduction in contrast medium dose based on lean body weight. HCC conspicuity on arterial phase images was the primary endpoint with a noninferiority margin of 0.2. Images were independently assessed by three radiologists; model-based iterative reconstruction (MBIR) images of the standard-contrast-dose group and low monoenergetic (50-keV) DLD images of the low-contrast-dose group were compared using a generalized estimating equation.
RESULTS: Ninety participants (age 59 ± 10 years; 68 men) were analyzed. Compared with the standard-contrast-dose group (n = 47), 40% less contrast media was used in the low-contrast-dose group (n = 43) (107.0 ± 17.1 mL vs. 64.5 ± 11.3 mL, p < 0.001). In the arterial phase, HCC conspicuity on 50-keV DLD images in the low-contrast-dose group was noninferior to that of MBIR images in the standard-contrast-dose group (2.92 vs. 2.56; difference, 0.36; 95% confidence interval, -0.13 to ∞; p = 0.013).
CONCLUSIONS: The contrast dose in liver CT can be reduced by 40% without impairing HCC conspicuity when using 50-keV and DLD techniques.
KEY POINTS: • In the arterial phase, hepatocellular carcinoma conspicuity on 50-keV deep learning-based denoising images in the low-contrast-dose group was noninferior to that of model-based iterative reconstruction images in the standard-contrast-dose group. • HCC detection was comparable between 50-keV deep learning-based denoising images in the low-contrast-dose group and model-based iterative reconstruction images in the standard-contrast-dose group.
引用
- Bae, Lee, Kim, et al. Low-contrast-dose liver CT using low monoenergetic images with deep learning-based denoising for assessing hepatocellular carcinoma: a randomized controlled noninferiority trial. Eur Radiol. 2022. PMID: 36576547. doi:10.1007/s00330-022-09298-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。